Written questions by Evans.

How much and what proportion of undergraduate medical tariff funding is used to support (a) wider NHS service delivery and (b) educational activities.

Awaiting answer.

Whether patients with recognised palliative or end-of-life care needs are subject to specific identification or prioritisation processes within accident and emergency departments.

Awaiting answer.

Whether he has made an assessment on the potential impact of introducing specific diagnostic or reporting time standards for patients with a limited or terminal prognosis.

Awaiting answer.

For what reason NHS England ceased collecting accountability reports on undergraduate medical tariff funding, and what alternative oversight arrangements are in place.

Awaiting answer.

What assessment he has made of whether NHS England’s diagnostic imaging turnaround time guidance is sufficient to meet the needs of patients with a recognised terminal diagnosis.

Awaiting answer.

Whether NHS England continues to collect annual accountability reports from NHS trusts on the expenditure of undergraduate medical tariff funding.

Awaiting answer.

What guidance exists for NHS providers on the timely communication of significant diagnostic findings to patients and their families where deterioration or recurrence of cancer is suspected.

Awaiting answer.

Whether the forthcoming Palliative Care and End-of-Life Care Modern Service Framework will include provisions relating to the timeliness of diagnostic results and communication for patients with a limited prognosis.

Awaiting answer.

What steps he is taking to ensure consistent access across Integrated Care Boards to non-hormonal menopause treatments, including fezolinetant.

Awaiting answer.

What assessment he has made of levels of regional variation in access to fezolinetant across England.

Awaiting answer.

What steps he is taking to ensure that patients are not disadvantaged when accessing NHS care after accessing treatment privately due to a previous lack of NHS availability.

Awaiting answer.

Whether national guidance has been issued to Integrated Care Boards on the prescribing of fezolinetant following its approval for NHS use.

Awaiting answer.

What guidance exists on shared care arrangements for patients seeking to transition from privately obtained medication to NHS prescriptions where those treatments later become available on the NHS.

Awaiting answer.

Whether he has had discussions with NHS England on access to fezolinetant within Leicester, Leicestershire and Rutland Integrated Care Board.

Awaiting answer.

Pursuant to WPQ 12787 answered on 11 November 2024 about Marriage, Relatives, whether he has commissioned advice on whether placing restrictions on first cousin marriage would require changes to the Sexual Offences Act 2003.

Awaiting answer.

With reference to WPQ 12787 answered on 11 November 2024 on Marriage: Relatives, what recent progress he has made on considering [i] marriage law and [ii] placing restrictions on marriages between first cousins.

Awaiting answer.

With reference to the press notice entitled 50,000 more young people to benefit from apprenticeships as Government unveils new skills reforms to get Britain working, published in December 2025, if he will take steps to ensure comparable investment within non-mayoral strategic authorities for linking young people with employers for apprenticeship opportunities.

Awaiting answer.

Pursuant to WPQ 106603 answered on 26 January 2026 about Marriage Relatives, what recent discussions the National Disease Registration Service has had with hospital trusts on improve the quality and completeness of data arising from health issues due to first cousin marriage.

Awaiting answer.

If he will hold discussions with (a) local and national health bodies, (b) academics and (c) the Men's Health Strategy Stakeholder Group on the issues surrounding Anabolic Steroids, IPEDs and SARMS

Awaiting answer.

What recent steps he has taken to support the national rollout of the Leukaemia Best Practice Timed Pathway.

Awaiting answer.